arXiv · 2206.06110
Halting hyaluronidase activity with hyaluronan-based nanohydrogels: development of versatile injectable formulations
Abstract
Hyaluronan (HA) is among the most used biopolymers for viscosupplementation and cosmetic applications. However, the current injectable HA-based formulations present relevant limitations: I) unmodified HA is quickly degraded by endogenous hyaluronidases (HAase), resulting in short lasting properties; II) cross-linked HA, although shows enhanced stability against HAase, often contains toxic chemical cross-linkers. As such, herein, we present biocompatible self-assembled hyaluronan-cholesterol nanohydrogels (HA-CH NHs) able to bind to HAase and inhibit the enzyme activity in vitro, more efficiently than currently marketed HA-based cross-linked formulations (e.g. JonexaTM). HA-CH NHs inhibit HAase through a mixed mechanism, by which NHs bind to HAase with an affinity constant 7-fold higher than that of HA. Similar NHs, based on gellan-cholesterol, evidenced no binding to HAase, neither inhibition of the enzyme activity, suggesting this effect might be due to the specific binding of HA-CH to the active site of the enzyme. Therefore, HA-CH NHs were engineered into injectable hybrid HA mixtures or physical hydrogels, able to halt the enzymatic degradation of HA.
Explore related subjects
Keep this discovery
E. Montanari, N. Zoratto, L. Mosca, L. Cervoni, E. Lallana, R. Angelini, R. Matassa, T. Coviello, C. Di Meo, P. Matricardi. 2022-06-13. Halting hyaluronidase activity with hyaluronan-based nanohydrogels: development of versatile injectable formulations. https://doi.org/10.1016/j.carbpol.2019.06.004
Cite the original work for its findings. Save a collection to share your selection of sources.